Table 5.
Allogenic hematopoietic stem cell transplantation and engraftment syndrome, aGVHD incidence and description of conditioning regimen and aGVHD prophylaxis
| Author/year of study | Country | Conditioning regimen | Conditioning regimen detail | aGVHD prophylaxis | aGVHD detail |
aGVHD incidence |
|---|---|---|---|---|---|---|
| Ileri et al. (2016) [35] | Turkey |
MAC: 82% NMAC: 18% |
ATG-based conditioning regimen, BU-based conditioning regimen |
CsA40.8% CsA + MTX:59.2% |
Cyclosporine alone Cyclosporine: (3 mg/kg/day) on day -1 (PA) + Methotrexate: on day 1,3,6 |
The cumulative incidence of aGVHD grade II-IV was 12.4% on the 30th-day post-post-transplantation |
| Omer et al. (2014) [36] | USA |
MAC: 38.7% NMAC: 61.3% |
MAC: TBI-based conditioning regimen + CY combined with high dose BU Or NMAC: High dose CY and fludarabine + low dose BU |
CsA39.6% CsA + MTX:13.8% CsA + MMF:15.7% |
Cyclosporine 2.5 mg/kg/day alone Cyclosporine and methotrexate combined Cyclosporine and mycophenolate mofetil combined |
The incidence of aGVHD grade II-IV was 31% in ES ( +) and 23% in non-ES patients at 180th days post-post-transplantation |
| Chang et al. (2014) [37] | USA |
MAC: 63.1% RIC: 36.9% |
MAC: TBI ≥ 1200 Gy, CY 200 mg/kg, BU 16 mg/kg RIC: TBI reduced to 30% of MA and consisted mainly of FU + reduced doses of BU and Thiotepa |
Tac + MTX:59.7% Tac + MMF:40.3% |
Calcineurin inhibitor plus Methotrexate (n = 71) Calcineurin plus Mycophenolate mofetil (n = 48) |
The cumulative incidence of aGVHD grade II-IV was 74% on the 28th-day post-post-transplantation |
| Park et al. (2013) [38] | Korea |
MAC: 68.5% RIC: 31.5% |
MAC: TBI 13.2 Gy, CY 120 mg/kg, BU 16 mg/kg RIC: low dose TBI, BU 9 mg/kg, MEL 150 mg/m2 |
MTX STR |
Methotrexate and some non-specified steroids | The cumulative incidence of aGVHD grade II-IV was 56% on the 100th day post-post-transplantation |
| Wang et al. (2011) [39] | China |
MAC: 89% RIC: 11% |
MAC: BU/CY, BU/CY + ATG, TBI + Ara-c + CY, Flu + BU + CY RIC: Flu + BU + TBI + ATG, Flu + BU + CY + TBI |
CsA + MMF:100% | IV cyclosporine 3 mg/kg/day at day 1 followed by oral CsA 200-400 ng/ml for 1 month + Mycophenolate mofetil 20-30 mg/kg on day + 1 | The cumulative incidence of aGVHD grade II-IV was 35.5% on the 100th day post-post-transplantation |
| Kanda et al. (2013) [40] | USA |
MAC: 100% RIC: 0.0% |
MAC: FLU/TBI (n = 26), FLU/TBI/CY(n = 16), FLU/TBI/THIO (n = 7), FLU/TBI/MEL (n = 2), TBI/CY/ATG (n = 3), TBI/MEL/ATG (n = 3) RIC: Not used in any patient |
Tac + MMF:61% CsA + MMF:39% |
IV Tacrolimus (n = 35) combined with mycophenolate mofetil and Cyclosporine (n = 22) in combination with mycophenolate mofetil | Incidence of aGVHD grade II-IV was 61% in ES ( +), 36% for III-IV grade aGVHD at 100th-day post-post-transplantation |
Tac: Tacrolimus, CsA: Cyclosporine, MMF: mycophenolate mofetil, MTX: methotrexate, NMAC: non-myeloablative conditioning, MAC: myeloablative conditioning, RIC: reduced-intensity conditioning, MEL: melphalan, BU: busulfan, ATG: anti-thymocyte globulin, TBI: total body irradiation, FLU: Fludarabine, STR: steroid